SGLT2 inhibitor/ja: Difference between revisions
SGLT2 inhibitor/ja
Created page with "{{Oral hypoglycemics/ja}} {{Sodium-glucose transporter modulators/ja}} {{Portal bar | Medicine}}" Tags: Mobile edit Mobile web edit |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 163: | Line 163: | ||
このクラスの多能性作用は、ナトリウム利尿、血液濃縮、レニン-アンジオテンシン-アルドステロン系の不活性化、ケトン体形成、エネルギー[[homeostasis/ja|恒常性]]の変化、[[glycosuria/ja|糖尿]]、[[lipolysis/ja|脂肪分解]]、[[Anti-inflammatory/ja|抗炎症]]、[[Antioxidant/ja|抗酸化]]などの様々な薬力学的作用に起因している。 | このクラスの多能性作用は、ナトリウム利尿、血液濃縮、レニン-アンジオテンシン-アルドステロン系の不活性化、ケトン体形成、エネルギー[[homeostasis/ja|恒常性]]の変化、[[glycosuria/ja|糖尿]]、[[lipolysis/ja|脂肪分解]]、[[Anti-inflammatory/ja|抗炎症]]、[[Antioxidant/ja|抗酸化]]などの様々な薬力学的作用に起因している。 | ||
SGLT2阻害薬は、[[:en:NAFLD|NAFLD]]と2型糖尿病の患者を対象とした臨床試験において、また2型糖尿病でない患者を対象とした臨床試験において、肝機能に対する有益な効果を示している。 | |||
==外部リンク== | |||
* {{cite web | title=FDA revises label of diabetes drug canagliflozin | website=U.S. Food and Drug Administration | date=15 January 2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet }} | * {{cite web | title=FDA revises label of diabetes drug canagliflozin | website=U.S. Food and Drug Administration | date=15 January 2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet }} | ||
* {{cite web | title=FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) | website=U.S. Food and Drug Administration | date=18 May 2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine }} | * {{cite web | title=FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) | website=U.S. Food and Drug Administration | date=18 May 2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine }} | ||
| Line 175: | Line 172: | ||
* {{cite web | title=Warning use metformin in certain patients with reduced kidney function | website=U.S. Food and Drug Administration | date=14 November 2017 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain }} | * {{cite web | title=Warning use metformin in certain patients with reduced kidney function | website=U.S. Food and Drug Administration | date=14 November 2017 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain }} | ||
* {{cite web | title=Warning: infection of genital area with SGLT2 inhibitors for diabetes | website=U.S. Food and Drug Administration | date=7 September 2018 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes }} | * {{cite web | title=Warning: infection of genital area with SGLT2 inhibitors for diabetes | website=U.S. Food and Drug Administration | date=7 September 2018 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes }} | ||
{{Oral hypoglycemics/ja}} | |||
{{Oral hypoglycemics}} | {{Sodium-glucose transporter modulators/ja}} | ||
{{Sodium-glucose transporter modulators}} | |||
{{Portal bar | Medicine}} | {{Portal bar | Medicine}} | ||
[[Category:SGLT2 inhibitors| ]] | [[Category:SGLT2 inhibitors| ]] | ||
[[Category:Anti-diabetic drugs]] | [[Category:Anti-diabetic drugs]] | ||